Key facts
- Adaptyv Bio’s last known valuation is $13.4M (Sep 2021).
- It has raised $11.2M; the latest was Seed Round ($8.0M) in Sep 2025.
- Notable investors include Y Combinator, Venture Kick, Acequia Capital, Ecole Polytechnique Federale de Lausanne, Hawktail — 21 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for Adaptyv Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Adaptyv Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Adaptyv Bio
Developer of a protein engineering technology intended to identify new antibodies to combat different diseases. The company's technology closes the loop between computational prediction and experimental validation with cell-free synthetic biology and high-throughput nanofluidic, enabling physicians to improve patient outcomes.
- Sector
- Healthcare
- HQ
- Lausanne, Switzerland
- Founded
- 2020
- Employees
- 22
- Website
- adaptyvbio.com/
- Ownership
- Privately Held (backing)
Adaptyv Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Adaptyv Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Adaptyv Bio in its N-PORT filings yet. We sweep new filings monthly.